4-甲基-4,5,6,7-四氢噻吩并[3,2-c]吡啶 | 92503-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 4-甲基-4,5,6,7-四氢噻吩并[3,2-c]吡啶
• 中文别名: 4-甲基-4,5,6,7-四氢噻吩并[3,2-C]吡啶
• 英文名称: 4-Methyl-4,5,6,7-tetrahydro-thieon<3,2-c>pyridin
• 英文别名: 4-methyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
• CAS: 92503-61-2
• 化学式: C₈H₁₁NS
• mdl: MFCD07366382
• 分子量: 153.248
• InChiKey: IKTLCKCXJUXCSP-UHFFFAOYSA-N

物化性质

• 沸点：
  124°/0.1mm
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-氯吡唑并[1,5-a]嘧啶-2-羧酸 、 4-甲基-4,5,6,7-四氢噻吩并[3,2-c]吡啶 生成 (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)(4-methyl-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methanone
  参考文献：
  名称：

  Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

  摘要：

  本发明涉及公式（I）的吡唑并嘧啶衍生物，其中：Y1、Y2和Y3独立地为CR10、NH、S或O等；其中至少一个Y1、Y2和Y3代表CR10；R1代表氯或溴；R2、R3、R4、R5、R6和R7代表氢或C1-C6烷基等；R10代表氢、卤素或苯基等；这些衍生物是有效的mGluR5调节剂，例如用于治疗各种神经系统疾病。

  公开号：

  US07947689B2
• 作为产物：
  描述：

  5-formyl-4-methyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine 在 盐酸 、 水 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以100%的产率得到4-甲基-4,5,6,7-四氢噻吩并[3,2-c]吡啶
  参考文献：
  名称：

  An Efficient and Convenient Synthesis of 4,5,6,7-Tetrahydrothieno[3,2-c]pyridines by a Modified Pictet-Spengler Reaction via a Formyliminium Ion Intermediate

  摘要：

  A synthesis of N-formyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridines (5) was achieved in a highly efficient manner via trifluoroacetic acid catalyzed cyclization of formyliminium ion (4), which was produced by imination of 2-(2-thienyl)ethylamine (1) and a carbonyl compound (2) using titanium(IV) tetraisopropoxide followed by formylation with acetic-formic anhydride in a one-pot procedure. This modified Pictet-Spengler reaction provides a convenient method for preparing 4,5,6,7-tetahydrothieno[3,2-c]pyridines (6) possessing various substituents at C-4.

  DOI：

  10.3987/com-10-11992

文献信息

• [EN] RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRAZOLO- ET TRIAZOLO-PYRIMIDINE ANTIVIRAUX DU VIRUS RESPIRATOIRE SYNCYTIAL (VRS)
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：WO2016174079A1

  公开（公告）日：2016-11-03

  The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.

  这项发明涉及具有抗病毒活性的新型取代吡唑并三唑基嘧啶化合物，其化学式为(I)，特别是对呼吸道合胞病毒（RSV）复制具有抑制活性。该发明还涉及包含这些化合物的药物组合物，以及用于治疗呼吸道合胞病毒感染的化合物。
• Quinoline and naphthyridine carboxylic acid antibacterials
  申请人：——

  公开号：US20020049223A1

  公开（公告）日：2002-04-25

  Compounds having formula (I) 1 or pharmaceutically acceptable salts or prodrugs thereof, are useful as antibacterial agents.

  具有化学式(I)1的化合物或其药用可接受的盐或前药，可用作抗菌剂。
• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Danysz Wojciech

  公开号：US20080039476A1

  公开（公告）日：2008-02-14

  The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y 1 , Y 2 and Y 3 independently are e.g. CR 10 , NH, S or O, whereby at least one of Y 1 , Y 2 and Y 3 represents CR 10 ; R 1 represents chloro or bromo; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 represent e.g. hydrogen or C 1 -C 6 -alkyl, and R 10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.

  本发明涉及式(I)的吡唑并嘧啶衍生物，其中Y1、Y2和Y3独立地是例如CR10、NH、S或O，其中至少一个Y1、Y2和Y3代表CR10；R1代表氯或溴；R2、R3、R4、R5、R6和R7代表例如氢或C1-C6烷基，而R10代表例如氢、卤素或苯基。这些化合物是有效的mGluR5调节剂，例如用于治疗各种神经系统疾病。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Agents And Methods For Treating Ischemic And Other Diseases
  申请人：Sun Xiujun

  公开号：US20140221423A1

  公开（公告）日：2014-08-07

  This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.

  本发明涉及调节TRPM7蛋白活性的化合物及其在缺血、癌症、疼痛或青光眼的治疗或预防中的应用。